In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation

Biological and Pharmaceutical Bulletin

Volumn 22, Issue 9, 1999, Pages 971-974

  Suzumura, Kuniharu ^a   Odawara, Akio ^a   Yasuhara, Mikiko ^a   Tanaka, Keiko ^a   Narita, Hiroshi ^a   Suzuki, Toshikazu ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Antioxidant; Conjugated diene; Fluvastatin; HMG CoA reductase inhibitor; Lipid peroxidation; Low density lipoprotein

Indexed keywords

ANTILIPEMIC AGENT; COPPER; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; ISOMERISM; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; RACEMIC MIXTURE;

EID: 0032822701     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.22.971     Document Type: Article

References (23)

1. Steinberg D., Atherosclerosis, 131 (Suppl.), S5-S7 (1997).
2. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L., N. Engl. J. Med., 320, 915-924 (1989).
3. Witztum J. L., Steinberg D., J. Clin. Invest., 88, 1785-1792 (1991).
4. Boyd H. C., Gown A. M., Wolfbauer G., Chait A., Am. J. Pathol., 135, 815-825 (1989).
5. Haberland M. E., Fong D., Cheng L., Science, 241, 215-218 (1988).
6. Ylä-Herttuala S., Palinski W., Rosenfeld M. E., Parthasarathy S., Carew T. E., Butler S., Witztum J. L., Steinberg D., J. Clin. Invest., 84, 1086-1095 (1989).
7. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H., Kawai C., Proc. Natl. Acad. Sci. U.S.A., 84, 5928-5931 (1987).
8. Carew T. E., Schwenke D. C., Steinberg D., Proc. Natl. Acad. Sci. U.S.A., 84, 7725-7729 (1987).
9. Rice-Evans C. A., Diplock A. T., Free. Rad. Biol. Med., 15, 77-96 (1993).
10. Plosker G. L., Wagstaff A. J., Drugs, 51, 433-459 (1996).
11. Brown W. V., Am. J. Cardiol., 73, 1D-61D (1994).
12. Suzumura K., Yasuhara M., Tanaka K., Suzuki T., Biochem. Pharmacol., 57, 697-703 (1999).
13. Hussein O., Schlezinger S., Rosenblat M., Keider S., Aviram M., Atherosclerosis, 128, 11-18 (1997).
14. Aviram M., Hussein O., Rosenblat M., Schlezinger S., Hayek T., Keidar S., J. Cardiovasc. Pharmacol., 31, 39-45 (1998).
15. Mitani H., Bandoh T., Ishikawa J., Kimura M., Totsuka T., Hayashi S., Brit. J. Pharmacol., 119, 1269-1275 (1996).
16. Corsini A., Mazzotti M., Raiteri M., Soma M. R., Gabbiani G., Fumagalli R., Paoletti R., Atherosclerosis, 101, 117-125 (1993).
17. Dain J. G., Fu E., Gorski J., Nicoleti J., Scallen T. J., Drug. Metab. Dispos., 21, 567-572 (1993).
18. Nakashima A., Ohtawa M., Masuda N., Morikawa H., Bando T., Yakugaku Zasshi, 119, 93-99 (1999).
19. Havel R. J., Eder H. A., Bragdon J. H., J. Clin. Invest., 34, 1345-1353 (1955).
20. Bergmann A., Ramos P., Esterbauer H., Winklhofer-Roob B. M., J. Lipid. Res., 38, 2580-2588 (1997).
21. Daugherty A., Roselaar S. E., Cardiovasc. Res., 29, 297-311 (1995).
22. Bjorkhem I., Henriksson-Freyschuss A., Breuer O., Berglund L., Henriksson P., Arteriosclero. Thromb., 11, 15-22 (1991).
23. Rice-Evans C. A., Miller N. J., Paganga G., Free. Rad. Biol. Med., 20, 933-956 (1996).